person · Reporting owner

Strobeck Matthew

Disclosed activity across 5 companies

Tapewire entity: 42321
SEC CIK: 0001377832

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Accelerate Diagnostics, IncAXDX · Entity 78156	Director	January 23, 2024	January 25, 2024
BIODESIX INCBDSX · Entity 6053	Director	January 02, 2026	January 06, 2026
ELUTIA INC.ELUT · Entity 7342	10% owner in previous filing	March 23, 2023	February 20, 2024
QuidelOrtho CorpQDEL · Entity 4986	Director	May 29, 2026	June 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Accelerate Diagnostics, Inc

Report date January 23, 2024 · Filed January 25, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Birchview Fund, LLC	120,682	Reported balance After 2024-01-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 120,682 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2029-01-23	IndirectBy Birchview Fund, LLC	100,000	Reported balance After 2024-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 100,000 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	202,556	Reported balance Holding disclosure · report date 2024-01-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 202,556
Common StockSEC Table I · non-derivative	IndirectAs UGMA Custodian for minor children	2,000	Reported balance Holding disclosure · report date 2024-01-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 2,000

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.

F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

BIODESIX INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	6,804	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 6,804 · Balance 6,804 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01	Direct	6,354	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

ELUTIA INC.

Report date March 23, 2023 · Filed February 20, 2024 · Amendment

Jointly reported with Birchview Capital, LP, Birchview Fund LLC

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,615,184	Reported balance After 2023-03-23 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-03-23 · Purchase · Acquired 100,000 · Balance 1,615,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,625,184	Reported balance After 2023-03-23 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2023-03-23 · Purchase · Acquired 10,000 · Balance 1,625,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,643,184	Reported balance After 2023-03-24 transaction · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · 2023-03-24 · Purchase · Acquired 18,000 · Balance 1,643,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,645,184	Reported balance After 2023-03-24 transaction · row 4 Amendment: may correct only part of an earlier disclosure. 1 source row Row 4 · 2023-03-24 · Purchase · Acquired 2,000 · Balance 1,645,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,655,184	Reported balance After 2023-03-27 transaction · row 5 Amendment: may correct only part of an earlier disclosure. 1 source row Row 5 · 2023-03-27 · Purchase · Acquired 10,000 · Balance 1,655,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above.

Filing footnotes · ownership attribution and instrument terms

F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund.

F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.

F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").

F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above.

QuidelOrtho Corp

Report date May 29, 2026 · Filed June 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,604	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Grant · Acquired 6,829 · Balance 34,604 F1: Reflects release of restricted stock units that were previously reported on a Form 4.
Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Exercise / conversion · Disposed 6,829 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5: The restricted stock units vested on May 29, 2026.
Common StockSEC Table I · non-derivative	IndirectUGMA Account	16,630	Reported balance Holding disclosure · report date 2026-05-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 16,630 F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBirchview	38,145	Reported balance Holding disclosure · report date 2026-05-29 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 38,145 F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects release of restricted stock units that were previously reported on a Form 4.

F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

F5: The restricted stock units vested on May 29, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

QUIDEL CORP /DE/

Report date May 27, 2022 · Filed June 01, 2022

Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-05-27 transaction · row 1 1 source row Row 1 · 2022-05-27 · Disposition to issuer · Disposed 6,533 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
Common StockSEC Table I · non-derivative	IndirectUGMA Account	Reported balance After 2022-05-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-05-27 · Disposition to issuer · Disposed 16,630 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBirchview	Reported balance After 2022-05-27 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-05-27 · Disposition to issuer · Disposed 38,145 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $53.27 · Expires 2028-04-04	Direct	Reported balance After 2022-05-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-27 · Disposition to issuer · Disposed 259 · Balance 0 F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5: Vested in full.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-27 · Disposition to issuer · Disposed 875 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-27 · Disposition to issuer · Disposed 262 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-05-27 · Disposition to issuer · Disposed 427 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-05-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-05-27 · Disposition to issuer · Disposed 85 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.

F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F5: Vested in full.

F6: Each restricted stock unit represents the right to receive one share of Quidel common stock.

F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).

F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 20, 2021 Filed May 24, 2021 21:59 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	35,168	$0.00 Strike: $7.68	$0.00	Disclosure SEC source: 0001104659-21-071497 · tm2117458d6_form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,168 Underlying: Common Stock · 35,168 shares Expires 2031-05-20 F1 · derivative.exercise_date: The option vests in full on May 20, 2022. Read SEC document
May 18, 2021 Filed May 20, 2021 20:42 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Premium) · Derivative	85	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034713 · doc4.xml · derivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85 Underlying: Common Stock · 85 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. Read SEC document
May 18, 2021 Filed May 20, 2021 20:42 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Converted) · Derivative	427	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034713 · doc4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427 Underlying: Common Stock · 427 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 18, 2021. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 18, 2021. Read SEC document
May 18, 2021 Filed May 20, 2021 20:42 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Equity Grant) · Derivative	1,624	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034713 · doc4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 1,624 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. Read SEC document
May 12, 2021 Filed May 14, 2021 20:15 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionRestricted Stock Units · Derivative	1,040	$0.00	$0.00	Disclosure SEC source: 0001209191-21-032981 · doc4.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,040 shares Expires 2021-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
May 12, 2021 Filed May 14, 2021 20:15 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionCommon Stock	1,040	$0.00	$0.00	Disclosure SEC source: 0001209191-21-032981 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document
April 09, 2021 Filed Apr 13, 2021 16:21 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantCommon Stock	19,531	$7.68	$149,998.08	Disclosure SEC source: 0001628280-21-006840 · wf-form4_161834525463287.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund, LLC Disclosed balance after: 187,297 F1 · shares: Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the second tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The second tranche of the offering closed on April 9, 2021. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
February 19, 2021 Filed Feb 24, 2021 13:08 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantCommon Stock	19,531	$7.68	$149,998.08	Disclosure SEC source: 0001104659-21-027338 · tm217603d5_4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund, LLC Disclosed balance after: 167,766 F1 · shares: Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the first tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The first tranche of the offering closed on February 19, 2021. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
December 07, 2020 Filed Dec 10, 2020 02:47 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionStock Options (Right to Buy) · Derivative	23,440	$0.00 Strike: $6.83	$0.00	Disclosure SEC source: 0000905148-20-001264 · form4.xml · derivative · entry 11 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,718 Underlying: Common Stock · 23,440 shares Expires 2030-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vests in 12 successive, equal monthly installments measured from April 1, 2020. Read SEC document
December 07, 2020 Filed Dec 10, 2020 02:47 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionStock Options (Right to Buy) · Derivative	35,157	$0.00 Strike: $6.83	$0.00	Disclosure SEC source: 0000905148-20-001264 · form4.xml · derivative · entry 10 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 35,157 shares Expires 2029-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested in 12 successive, equal monthly installments measured from April 1, 2019. Read SEC document
December 07, 2020 Filed Dec 10, 2020 02:47 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	23,440	$6.83	$160,095.20	Disclosure SEC source: 0000905148-20-001264 · form4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 07, 2020 Filed Dec 10, 2020 02:47 UTC	BIODESIX INC BDSX · Entity 6053	Exercise / conversionCommon Stock	35,157	$6.83	$240,122.31	Disclosure SEC source: 0000905148-20-001264 · form4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Conversion3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00 Strike: $14.40	$50,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 28 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 0 Underlying: Common Stock · 3,522 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Conversion3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00 Strike: $14.40	$50,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 27 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 0 Underlying: Common Stock · 3,522 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Conversion3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00 Strike: $14.40	$50,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 26 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 0 Underlying: Common Stock · 3,522 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Conversion3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00 Strike: $14.40	$50,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 25 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 0 Underlying: Common Stock · 3,522 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Conversion3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00 Strike: $14.40	$1,076,380.43	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 24 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,631 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Conversion3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00 Strike: $14.40	$260,937.14	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 23 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Clajer Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 18,714 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F2 · ownership.direct: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionSeries H Preferred Stock · Derivative	130,433	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 16 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Clajer Capital LLC Disclosed balance after: 0 Underlying: Common Stock · 21,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionSeries H Preferred Stock · Derivative	836,231	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 15 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,877 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionSeries G Preferred Stock · Derivative	1,660,268	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 14 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 279,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionSeries F Preferred Stock · Derivative	903,516	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 13 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionSeries E Preferred Stock · Derivative	750,907	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 12 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionSeries D Preferred Stock · Derivative	686,250	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 11 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionSeries C Preferred Stock · Derivative	100,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 10 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	PurchaseCommon Stock	83,333	$18.00	$1,499,994.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 9 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 83,333 F4 · ownership.direct: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F4 · ownership.nature: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	3,522	$14.40	$50,716.80	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 8 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 3,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	3,522	$14.40	$50,716.80	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 7 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 3,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	3,522	$14.40	$50,716.80	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 6 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 3,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	3,522	$14.40	$50,716.80	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 5 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 3,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	76,631	$14.40	$1,103,486.40	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	18,714	$14.40	$269,481.60	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Clajer Capital LLC Disclosed balance after: 40,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.direct: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	21,973	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Clajer Capital LLC Disclosed balance after: 21,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	ConversionCommon Stock	831,747	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. Read SEC document
September 03, 2020 Filed Sep 4, 2020 19:09 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	PurchaseCommon Stock	50	$155.60	$7,779.85	Disclosure SEC source: 0001209191-20-049663 · doc4.xml · nonDerivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Birchview Disclosed balance after: 38,145 F2 · balance_after: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
September 03, 2020 Filed Sep 4, 2020 19:09 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	PurchaseCommon Stock	350	$155.64	$54,474.00	Disclosure SEC source: 0001209191-20-049663 · doc4.xml · nonDerivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Birchview Disclosed balance after: 38,095 F2 · balance_after: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
September 02, 2020 Filed Sep 4, 2020 19:09 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	PurchaseCommon Stock	300	$167.74	$50,320.50	Disclosure SEC source: 0001209191-20-049663 · doc4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Birchview Disclosed balance after: 37,745 F2 · balance_after: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
September 02, 2020 Filed Sep 4, 2020 19:09 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	PurchaseCommon Stock	7,000	$166.60	$1,166,190.20	Disclosure SEC source: 0001209191-20-049663 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Birchview Disclosed balance after: 37,445 F1 · price: The weighted average purchase price for these transactions was $166.5986 per share, with a range of $166.545 to $166.78 per share and were made by the Birchview Fund and Birchview Capital accounts. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price. F2 · balance_after: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 18, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Grant3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00	$25,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 22 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: Not disclosed Underlying: Common Stock · 1,755 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 18, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Grant3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00	$25,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 21 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: Not disclosed Underlying: Common Stock · 1,755 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 18, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Grant3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00	$25,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 20 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: Not disclosed Underlying: Common Stock · 1,755 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 18, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Grant3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00	$25,000.00	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 19 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: Not disclosed Underlying: Common Stock · 1,755 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 18, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Grant3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00	$206,997.20	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 18 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 14,534 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. Read SEC document
June 18, 2020 Filed Nov 3, 2020 23:24 UTC	BIODESIX INC BDSX · Entity 6053	Grant3% Convertible Debt due June 2021 · Derivative	Not disclosed	$0.00	$5,468.57	Disclosure SEC source: 0001209191-20-056750 · doc4.xml · derivative · entry 17 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Clajer Capital LLC Disclosed balance after: Not disclosed Underlying: Common Stock · 383 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F2 · ownership.direct: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 14, 2020 Filed May 18, 2020 20:19 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionRestricted Stock Units · Derivative	2,100	$0.00	$0.00	Disclosure SEC source: 0001209191-20-030277 · doc4.xml · derivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. F5 · derivative.expiration_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. Read SEC document
May 14, 2020 Filed May 18, 2020 20:19 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	Exercise / conversionCommon Stock	2,100	$0.00	$0.00	Disclosure SEC source: 0001209191-20-030277 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. F2 · balance_after: In addition to these shares, the Reporting Person has sole voting and dispositive power with respect to 30,445 shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F3 · balance_after: In addition to these shares, the Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 12, 2020 Filed May 14, 2020 19:59 UTC	QUIDEL CORP /DE/ QDEL · Entity 126712	GrantRestricted Stock Units (Equity Grant) · Derivative	1,040	$0.00	$0.00	Disclosure SEC source: 0001209191-20-029391 · doc4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040 Underlying: Common Stock · 1,040 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 12, 2021. F2 · derivative.expiration_date: The restricted stock units vest on May 12, 2021. Read SEC document
April 01, 2020 Filed Apr 3, 2020 12:21 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GrantStock Option (right to buy) · Derivative	13,779	$0.00 Strike: $8.33	$0.00	Disclosure SEC source: 0001628280-20-004573 · wf-form4_158593088768476.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,779 Underlying: Common Stock · 13,779 shares Expires 2030-04-01 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, with the first installment vesting on May 1, 2020. Read SEC document
March 18, 2020 Filed Mar 20, 2020 12:31 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GiftCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001628280-20-003862 · wf-form4_158472188174024.xml · nonDerivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As UGMA Custodian for minor children Disclosed balance after: 20,000 F2 · kind: The reporting person transferred 5,000 shares to each of his four children, totaling 20,000 shares, under the Uniform Gifts to Minors Act. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
March 18, 2020 Filed Mar 20, 2020 12:31 UTC	Accelerate Diagnostics, Inc AXDX · Entity 78156	GiftCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001628280-20-003862 · wf-form4_158472188174024.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,025,560 F2 · kind: The reporting person transferred 5,000 shares to each of his four children, totaling 20,000 shares, under the Uniform Gifts to Minors Act. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.